Beijing Anzhen Hospital
Beijing 100029
2 studies enrolling now · 14 studies all time
What they study most
Arrhythmia, Atrial Fibrillation, Chronic Coronary Disease, Chronic Kidney Disease, Chronic Thromboembolic Pulmonary Hypertension, Congenital Heart Disease, Congenital Heart Disease With Fontan Circulation, Heart Failure, Hypertension, Pulmonary, Lipoprotein Disorder, Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Studies at this site
- Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a) — Recruiting now
- One-Month DAPT in CABG Patients — Recruiting now
- A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension — Running, not enrolling
- A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension — Running, not enrolling
- Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension — Running, not enrolling
- Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) — Completed
- EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) — Completed
- A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension — Stopped early
- Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects — Completed
- A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants — Stopped early
- An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients. — Stopped early
- A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure — Completed
- Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial — Completed
- GLORIA-AF Registry Program - Second and Third Phases — Completed